<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioorg Chem</journal-id><journal-id journal-id-type="iso-abbrev">Bioorg Chem</journal-id><journal-title-group><journal-title>Bioorganic Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0045-2068</issn><issn pub-type="epub">1090-2120</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7903152</article-id><article-id pub-id-type="pii">S0045-2068(21)00144-9</article-id><article-id pub-id-type="doi">10.1016/j.bioorg.2021.104767</article-id><article-id pub-id-type="publisher-id">104767</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Guo</surname><given-names>Sheng</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Xie</surname><given-names>Hang</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Lei</surname><given-names>Yu</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Liu</surname><given-names>Bin</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>Xu</surname><given-names>Yechun</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Zuo</surname><given-names>Zhili</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, 650201, China</aff><aff id="af010"><label>b</label>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</aff><aff id="af015"><label>c</label>School of Chemical Engineering, Sichuan University of Science &#x00026; Engineering, 180 Xueyuan Street, Huixing Road, Zigong, Sichuan 643000, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding authors.</corresp></author-notes><pub-date pub-type="pmc-release"><day>24</day><month>2</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>5</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>24</day><month>2</month><year>2021</year></pub-date><volume>110</volume><fpage>104767</fpage><lpage>104767</lpage><history><date date-type="received"><day>16</day><month>12</month><year>2020</year></date><date date-type="rev-recd"><day>24</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="graphical" id="ab005"><title>Graphical abstract</title><fig id="f0035" position="anchor"><graphic xlink:href="ga1_lrg"/></fig></abstract><abstract id="ab015"><p>SARS-CoV-2 is the pathogen that caused the global COVID-19 outbreak in 2020. Promising progress has been made in developing vaccines and antiviral drugs. Antivirals medicines are necessary complements of vaccines for post-infection treatment. The main protease (Mpro) is an extremely important protease in the reproduction process of coronaviruses which cleaves pp1ab over more than 11 cleavage sites. In this work, two active main protease inhibitors were found via docking-based virtual screening and bioassay. The IC<sub>50</sub> of compound VS10 was 0.20&#x000a0;&#x003bc;M, and the IC<sub>50</sub> of compound VS12 was 1.89&#x000a0;&#x003bc;M. The finding in this work can be helpful to understand the interactions of main protease and inhibitors. The active candidates could be potential lead compounds for future drug design.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Main protease</kwd><kwd>Virtual screening</kwd><kwd>Biochemical evaluation</kwd></kwd-group><kwd-group id="kg010"><title>Abbreviations</title><kwd>SARS-CoV-2, severe acute respiratory syndrome coronavirus 2</kwd><kwd>COVID-19, corona virus disease 2019</kwd><kwd>Mpro, main protease</kwd><kwd>IC<sub>50</sub>, Half maximal inhibitory concentration</kwd><kwd>MERS-CoV, middle east respiratory syndrome coronavirus</kwd><kwd>HCoV-OC43, Human coronavirus OC43</kwd><kwd>HCoV-NL63, Human coronavirus NL63</kwd><kwd>HCoV-HKU1, Human coronavirus Hong Kong University 1</kwd><kwd>HCoV-229E, Human coronavirus 229E</kwd><kwd>UTR, untranslated regions</kwd><kwd>ORF, open reading frame genes</kwd><kwd>pp1a, polyprotein 1a</kwd><kwd>pp1ab, polyprotein 1ab</kwd><kwd>3CLpro, 3C-like protease</kwd><kwd>PLP, papain-like proteases</kwd><kwd>nsps, non-structural proteins</kwd><kwd>S, spike glycoprotein</kwd><kwd>E, envelope protein</kwd><kwd>M, membrane protein</kwd><kwd>N, Nucleocapsid protein</kwd><kwd>ER, endoplasmic reticulum</kwd><kwd>PDB, protein data bank</kwd><kwd>DS 4.0, Discovery Studio 4.0</kwd><kwd>PAINS, pan assay interference compounds</kwd><kwd>BBB, blood brain barrier penetration</kwd><kwd>CYP450, cytochrome P450</kwd><kwd>HIA, human intestinal absorption</kwd><kwd>RMSD, root mean square difference</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0020">At the end of 2019, a coronavirus that swept the world was named SARS-CoV-2 by the International Committee on Taxonomy. The disease caused was named COVID-19 by the World Health Organization <xref rid="b0005" ref-type="bibr">[1]</xref>. SARS-CoV-2 has a strong infectious ability that seriously threatening human life worldwide. This kind of virus can cause diseases in humans and infect mammals <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, and the infected people or animals may become carriers of respiratory, intestinal, liver, and nervous system diseases <xref rid="b0025" ref-type="bibr">[5]</xref>. Prior to SARS-CoV-2, six types of coronaviruses can infect humans, including two highly lethal coronaviruses, namely severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), four types of coronaviruses that can cause mild upper respiratory diseases, named HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1 <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>.</p><p id="p0025">SARS-CoV-2 is a single positive-stranded RNA virus belonging to the genus Coronavirus &#x003b2; <xref rid="b0040" ref-type="bibr">[8]</xref>. The complete sequencing of the SARS-CoV-2 genome has untranslated regions (UTR) at both ends and at least 6 complete open reading frame genes (ORF) <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>. The first ORF (ORF 1a / b) directly translates two polyproteins: polyprotein 1a (pp 1a) and polyprotein 1ab (pp 1ab). These polyproteins are processed by the main protease (Mpro), also known as 3C-like protease (3CLpro), and one or two papain-like proteases (PLP) to become 16 non-structural proteins (nsps) <xref rid="b0055" ref-type="bibr">[11]</xref>. These nsps are involved in the production of subgenomic RNA, which encodes four major structural proteins, namely surface spike glycoprotein (S), envelope protein (E), membrane protein (M) and Nucleocapsid protein (N) <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. Then proteins are collected with new RNA genome assembly in the endoplasmic reticulum (ER) and Golgi-apparatus <xref rid="b0070" ref-type="bibr">[14]</xref>.</p><p id="p0030">Mpro plays a vital role in the replication cycle of the coronavirus, because the Mpro operates at more than 11 cleavage sites on the pp1ab <xref rid="b0075" ref-type="bibr">[15]</xref>. The recognition sequence is Leu-Gln for most of 11 sites <xref rid="b0080" ref-type="bibr">[16]</xref>. Inhibiting the activity of Mpro would block viral replication and would essentially block viral replication <xref rid="b0085" ref-type="bibr">[17]</xref>. There are no known homologs of Mpro in humans with identical cleavage specificity. Hence, its inhibition is unlikely to show side effects, making it an attractive target for COVID-19 drugs. In previous studies, the Mpro inhibitors have been discovered, including natural and derived bio-active compounds <xref rid="b0070" ref-type="bibr">[14]</xref>, major metabolites from spices <xref rid="b0075" ref-type="bibr">[15]</xref>, bioactive molecules from tea plant <xref rid="b0085" ref-type="bibr">[17]</xref>, herbal plants <xref rid="b0090" ref-type="bibr">[18]</xref> and acridinedione analogs <xref rid="b0095" ref-type="bibr">[19]</xref>. However, there is still no effective small molecular medicines available in clinic currently.</p><p id="p0035">In this work, we tried to identify the inhibitors of Mpro by docking-based virtual screening and the biochemical evaluation against the Specs database. Then, we explored and compared the interaction modes between compounds obtained and known Mpro inhibitors. This work tried to provide a rapid discovery of Mpro inhibitors which could be developed as drug lead compounds against the SARS-Cov-2.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><p id="p0040">In this work, docking-based virtual screening and biochemical evaluation were carried out to discover potential Mpro inhibitors. The three-dimensional crystal structure of Mpro of SARS-CoV-2 has been extracted from PDB database (PDB code: 6LU7; resolution: 2.16&#x000a0;&#x000c5;) <xref rid="b0100" ref-type="bibr">[20]</xref>. The working flow for this work is shown in <xref rid="f0005" ref-type="fig">Fig. 1</xref>
.<fig id="f0005"><label>Fig. 1</label><caption><p>The flowchart of discovery for Mpro inhibitors.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><sec id="s0015"><label>2.1</label><title>Preparation of protein</title><p id="p0045">Discovery Studio 4.0 (DS 4.0) was employed to prepare protein by adding missing residues, hydrogen atoms as well as removing water molecules and spectator ions <xref rid="b0105" ref-type="bibr">[21]</xref>. Then, the structure was minimized and optimized using Maestro 12.3 software (<ext-link ext-link-type="uri" xlink:href="http://www.schrodinger.com" id="ir005">www.schrodinger.com</ext-link>) with OPLS3e force field. The physical condition of pH was set as 7.0. This step optimized the structure, to relieve any strain and fine-tune the placement of various groups. Hydrogen atoms are always optimized fully, which allows relaxation of the H-bond network. Heavy atoms were optimized with converge of 0.3&#x000a0;&#x000c5;. Allowing movement of the heavy atoms can relieve structural strain, but will result in some deviation from the initial crystal structure.</p></sec><sec id="s0020"><label>2.2</label><title>Preparation of small molecules</title><p id="p0050">The 212,736 molecules from the Specs database (<ext-link ext-link-type="uri" xlink:href="http://www.specs.net" id="ir010">http://www.specs.net</ext-link>) were filtered by Lipinski and Veber rules, and 75,671 molecules were retained <xref rid="b0110" ref-type="bibr">[22]</xref>. A PAINS (Pan-Assay Interference Compounds) filtering was employed to remove false positive compounds using FAFDrugs4 (<ext-link ext-link-type="uri" xlink:href="https://fafdrugs4.rpbs.univ-paris-diderot.fr/" id="ir015">https://fafdrugs4.rpbs.univ-paris-diderot.fr/</ext-link>) <xref rid="b0115" ref-type="bibr">[23]</xref>. The ADMET evaluation was then carried out in DS 4.0 including aqueous solubility, blood brain barrier penetration (BBB), cytochrome P450 (CYP450) 2D6 inhibition, hepatotoxicity, human intestinal absorption (HIA) and plasma protein binding. The intestinal absorption model includes 95% and 99% confidence ellipses in the ADMET_PSA_2D, ADMET_AlogP98 plane <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>. There were 69,946 molecules retained via PAINS filtering and then 65,090 molecules retained via ADMET evaluation. The prepared ligand database was used to generate 3D conformational set for each molecule using CAESAR in DS 4.0 (<ext-link ext-link-type="uri" xlink:href="http://www.accelrys.com" id="ir020">http://www.accelrys.com</ext-link>). A maximum of 255 conformations within 20&#x000a0;kcal/mol in energy from the global minimum was generated. These structures were used for the next docking simulation.</p></sec><sec id="s0025"><label>2.3</label><title>Docking by LibDock</title><p id="p0055">The Dock Ligands (LibDock) protocol is developed by Diller and Merz <xref rid="b0130" ref-type="bibr">[26]</xref>. The binding site was defined by the position of original ligand. The protein site features used in LibDock is referred to as Hot Spots (polar and apolar). A polar Hotspot is preferred by a polar ligand atom, for example, a hydrogen bond donor or acceptor. An apolar Hot Spot is preferred by an apolar atom, for example, a carbon atom. The receptor Hot Spot file is calculated prior to the docking procedure. The rigid ligand poses were put into the active site and Hot Spots were matched as triplets. The poses were pruned and a final optimization step was performed before the poses were scored.</p></sec><sec id="s0030"><label>2.4</label><title>Docking by GOLD</title><p id="p0060">GOLD (<ext-link ext-link-type="uri" xlink:href="https://www.ccdc.cam.ac.uk" id="ir025">https://www.ccdc.cam.ac.uk</ext-link>) was selected for precise docking simulation of ligands from previous step. GOLD can make high database enrichments and identify the correct binding mode reliably.</p><p id="p0065">The retained candidates by LibDock were further screened using the GOLD docking program <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>. At the same time, 8 published Mpro inhibitors were selected as templates to do structure similarity screening in Specs <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, exhibited in <xref rid="t0010" ref-type="table">Table 2</xref>.</p><p id="p0070">There were 3 templates and 3 scoring functions available to evaluate the quality of the docking. The binding pocket was defined within 7&#x000a0;&#x000c5; from the co-crystallised ligand. The co-crystallised ligand was docked back to the binding pocket to find the most suitable score function. The combination of goldscore_p450_csd and CHEMPLP gave the highest score (117.86) and low RMSD (2.5498&#x000a0;&#x000c5;) as illustrated in <xref rid="t0005" ref-type="table">Table 1</xref>
. They were thus selected for docking simulation. The value of GA runs was set to 50 times.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>The Score and RMSD of Different Score Functions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Fitness&#x00026;Search Options</th><th colspan="2">CHEMPLP<hr/></th><th colspan="2">GoldScore<hr/></th><th colspan="2">ChemScore<hr/></th></tr><tr><th>Templates</th><th>Score</th><th>RMSD(&#x000c5;)</th><th>Score</th><th>RMSD(&#x000c5;)</th><th>Score</th><th>RMSD(&#x000c5;)</th></tr></thead><tbody><tr><td>chemscore_Kinase</td><td>101.48</td><td>2.4339</td><td>91.14</td><td>8.3199</td><td>28.15</td><td>4.3580</td></tr><tr><td>chemscore_p450_csd</td><td>92.04</td><td>12.0136</td><td>93.25</td><td>9.6106</td><td>32.13</td><td>2.2065</td></tr><tr><td>goldscore_p450_csd</td><td>117.86</td><td>2.5498</td><td>93.97</td><td>1.9502</td><td>29.77</td><td>4.4503</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Published Mpro Inhibitors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Name</th><th>structure</th><th>IC<sub>50</sub>(&#x003bc;M)</th></tr></thead><tbody><tr><td>1</td><td>Ebselen <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx1_lrg.gif"/></td><td>0.67<inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.09</td></tr><tr><td>2</td><td>Disumfiram <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx2_lrg.gif"/></td><td>9.35<inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.18</td></tr><tr><td>3</td><td>Tideglusib <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx3_lrg.gif"/></td><td>1.55<inline-formula><mml:math id="M3" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.30</td></tr><tr><td>4</td><td>Carfmofur <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx4_lrg.gif"/></td><td>1.82<inline-formula><mml:math id="M4" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.06</td></tr><tr><td>5</td><td>Shikonin <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx5_lrg.gif"/></td><td>15.75<inline-formula><mml:math id="M5" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>8.22</td></tr><tr><td>6</td><td>PX-12 <xref rid="b0145" ref-type="bibr">[29]</xref></td><td><inline-graphic xlink:href="fx6_lrg.gif"/></td><td>21.39<inline-formula><mml:math id="M6" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>7.06</td></tr><tr><td>7</td><td>11a <xref rid="b0055" ref-type="bibr">[11]</xref></td><td><inline-graphic xlink:href="fx7_lrg.gif"/></td><td>0.053<inline-formula><mml:math id="M7" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.005</td></tr><tr><td>8</td><td>11b <xref rid="b0055" ref-type="bibr">[11]</xref></td><td><inline-graphic xlink:href="fx8_lrg.gif"/></td><td>0.040<inline-formula><mml:math id="M8" altimg="si1.svg"><mml:mo>&#x000b1;</mml:mo></mml:math></inline-formula>0.002</td></tr></tbody></table></table-wrap></p></sec><sec id="s0035"><label>2.5</label><title>Cluster analysis</title><p id="p0075">Due to some molecules share the similar skeleton, Cluster Ligands was used to reduce repeatability and increase the hit rate. The remaining molecules were purchased for the biochemical evaluation.</p></sec><sec id="s0040"><label>2.6</label><title>The protein expression and purification of SARS-CoV-2 Mpro</title><p id="p0080">The protein expression and purification of SARS-CoV-2 Mpro has previously been described <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>. In brief, the cDNA of full-length SARS-CoV-2 Mpro (GenBank: MN908947.3) was cloned into the PGEX6p-1 vector. To obtain SARS-CoV-2 Mpro with authentic N and C terminals, four amino acids (AVLQ) were inserted between the GST tag and the full length SARS-CoV-2 Mpro, while eight amino acids (GPHHHHHH) were added to the C-terminus of SARS-CoV-2 Mpro. The plasmid was then transformed into BL21 (DE3) cells for protein expression. The <italic>N</italic>-terminal GST tag and four amino acids (AVLQ) were self-cleavable. The expressed protein with an authentic <italic>N</italic>-terminus was purified by a Ni-NTA column (GE Healthcare) and transformed into the cleavage buffer (150&#x000a0;mM NaCl, 25&#x000a0;mM Tris, pH 7.5) containing human rhinovirus 3C protease to remove the additional residues. The resulting protein sample was further passed through size-exclusion chromatography (Superdex200, GE Healthcare). The eluted protein samples were stored in a solution (10&#x000a0;mM Tris, pH 7.5) for the enzymatic inhibition assay.</p></sec><sec id="s0045"><label>2.7</label><title>The inhibition assay of SARS-CoV-2 Mpro</title><p id="p0085">The inhibition assay of SARS-CoV-2 Mpro has previously been described <xref rid="b0150" ref-type="bibr">[30]</xref>. In brief, the recombinant SARS-CoV-2 Mpro at a concentration of 30&#x000a0;nM was mixed with serial dilutions of each compound in 80&#x000a0;&#x000b5;L assay buffer (50&#x000a0;mM Tris-HCl, pH 7.3, 1&#x000a0;mM EDTA) and incubated for 10&#x000a0;min. Inhibitory activities of VS10 against SARS-CoV-2 Mpro were measured at different concentrations of 0.01, 0.02, 0.03, 0.06, 0.13, 0.25, 0.50, 1.00, 2.00, 4.00, 8.00, and 16.00&#x000a0;&#x000b5;M. Inhibitory activities of VS12 against SARS-CoV-2 Mpro were measured at different concentrations of 0.03, 0.06, 0.13, 0.25, 0.50, 1.00, 2.00, 4.00, 8.00, 16.00, 32.00, and 64.00&#x000a0;&#x000b5;M. For the other 35 molecules listed in Table S1 (<xref rid="s0085" ref-type="sec">supplementary material</xref>), we measured the inhibitory activity at a concentration of 10&#x000a0;&#x000b5;M. The reaction was initiated by adding 40&#x000a0;&#x000b5;L fluorogenic substrate (MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2) at a final concentration of 20&#x000a0;&#x000b5;M. After that, the fluorescence signal at 320&#x000a0;nm (excitation)/405&#x000a0;nm (emission) was measured immediately every 35&#x000a0;s for 3.5&#x000a0;min with a Bio-Tek Synergy4 plate reader. The initial velocities of reactions with compounds added at various concentrations compared to the reaction added with DMSO were calculated and used to generate inhibition profiles.</p><p id="p0090">For each compound, three independent experiments were performed for the determination of IC<sub>50</sub> value. The IC<sub>50</sub> values were expressed as the mean&#x000a0;&#x000b1;&#x000a0;SD and determined via nonlinear regression analysis using GraphPad Prism software 8.0 (GraphPad Software, Inc., San Diego, CA, USA).</p></sec></sec><sec id="s0050"><label>3</label><title>Results and discussion</title><sec id="s0055"><label>3.1</label><title>Virtual screening and molecular docking</title><p id="p0095">75,671 molecules were remained after Lipinski and Veber rules screening. After that, 69,946 molecules were obtained via PAINS filtering. Furthermore, we choose the intersection with a 95% confidence interval to retain 65,090 candidates by ADMET screening (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
). Then, those compounds were subjected to molecular docking using LibDock. The potential candidates after LibDock docking were selected for further study using GOLD. The Default docking mode by Gold was used to acquire top 2000 candidates including 898 compounds from similarity screening, and then the very flexible mode was used to acquire top 200 candidates. And then, 200 candidates were retained with the very flexible mode. The remaining compounds were clustered according to the structure similarity using DS 4.0. Finally, 37 molecules were selected as a small subset which represents 200 compounds.<fig id="f0010"><label>Fig. 2</label><caption><p>2D plot showing relationship between polar surface area and calculated AlogP98 values of the selected molecules.</p></caption><graphic xlink:href="gr2_lrg"/></fig></p></sec><sec id="s0060"><label>3.2</label><title>Biochemical evaluation</title><p id="p0100">The final selected 37 molecules were tested by biochemical evaluation, from which 2 compounds showed relative high biological activity (<xref rid="f0015" ref-type="fig">Fig. 3</xref>
and <xref rid="t0015" ref-type="table">Table 3</xref>
). The IC<sub>50</sub> of compound VS10 is 0.20&#x000a0;&#x003bc;M, and the IC<sub>50</sub> of compound VS12 is 1.89&#x000a0;&#x003bc;M.<fig id="f0015"><label>Fig. 3</label><caption><p>The IC<sub>50</sub> of compounds VS10 and VS12. Dose-response curves for IC<sub>50</sub> values were determined by nonlinear regression. All data are shown as mean&#x000a0;&#x000b1;&#x000a0;SD. Three independent experiments were performed.</p></caption><graphic xlink:href="gr3_lrg"/></fig><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Biochemical Evaluation of Two Lead Compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Structure</th><th>IC<sub>50</sub>(&#x003bc;M)</th></tr></thead><tbody><tr><td>VS10</td><td><inline-graphic xlink:href="fx9_lrg.gif"/></td><td>0.20&#x000a0;&#x000b1;&#x000a0;0.03</td></tr><tr><td>VS12</td><td><inline-graphic xlink:href="fx10_lrg.gif"/></td><td>1.89&#x000a0;&#x000b1;&#x000a0;0.22</td></tr></tbody></table></table-wrap></p></sec><sec id="s0065"><label>3.3</label><title>Interaction modes analysis</title><p id="p0105">We analyzed the interaction between these two small molecules and protein via DS 4.0, Pymol 2.2.3 and online server (<ext-link ext-link-type="uri" xlink:href="https://projects.biotec.tu-dresden.de/plip-web/plip/index" id="ir030">https://projects.biotec.tu-dresden.de/plip-web/plip/index</ext-link>) <xref rid="b0155" ref-type="bibr">[31]</xref>.</p><p id="p0110">Shown as <xref rid="f0020" ref-type="fig">Fig. 4</xref>
(A), the CO of compound VS10 formed four strong hydrogen bonds with GLY143, SER144 and CYS145. In addition, the SH of CYS145 also formed two weak hydrogen bonds with benzene ring and heterocycle. MET165 and GLU166 formed a hydrogen bond with two benzene rings, respectively. As presented in <xref rid="f0020" ref-type="fig">Fig. 4</xref> (C), the compound VS12 formed four hydrogen bonds and three hydrophobic interactions with Mpro. The CO respectively formed a hydrogen bond with GLU166 and GLN189, the ring of thiadiazole formed hydrophobic interactions with HIS41 and MET49. The benzene ring formed a hydrophobic interaction with MET165 as well. The NH<sub>2</sub> of VS12 formed a hydrogen bond with TYR54. The more important is that the S on VS12 formed a hydrogen bond with CYS145, which may be the location of covalent bonding. It can be seen from the interactions between these two small molecules with the protein. HIS41, CYS145, MET165 and GLU166 are the key amino acids for inhibitor binding.<fig id="f0020"><label>Fig. 4</label><caption><p>Binding modes between ligands and Mpro. A, C shows interactions between VS10, VS12 and protein amino acids in 3D, the green lines represent hydrogen bonds, the magentas lines represent hydrophobic interactions. B, D shows interactions between VS10, VS12 and protein amino acids in 2D by DS 4.0. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr4_lrg"/></fig></p></sec><sec id="s0070"><label>3.4</label><title>Interaction analysis</title><p id="p0115">N3 inhibitor simultaneously acts on S1, S2, S4 and S1&#x02032; subsites, as well as 11a and 11b. These small molecules have more interactions with Mpro, which makes them more stable together and shows a better inhibitory effect. VS10 acts on S1, S4 and S1&#x02032; subsites, while VS12 acts on S1, S2, S4 and S1&#x02032; subsites. In contrast to the numerous stabilizing interactions of N3, VS10 and VS12 interacts mainly with CYS145 through van der Waals and hydrogen bonding interactions, as well as carmofur <xref rid="b0160" ref-type="bibr">[32]</xref>. Ebselen interacts through hydrogen bonding interactions mainly with GLU166 and van der Waals interactions with MET49 and MET165 in the hydrophobic S2 binding area <xref rid="b0160" ref-type="bibr">[32]</xref>. VS10 is very similar to ebselen, but IC<sub>50</sub> is more than three times stronger. Considering the wide binding area of Mpro, in our work, VS10 forms more hydrogen bonds and hydrophobic interaction contrasts to the ebselen, so, VS10 shows more effective inhibition. MS/MS analysis has revealed that ebselen, PX-12, and carmofur were able to covalently modify the catalytic cysteine CYS145 of SARS-CoV-2 Mpro <xref rid="b0145" ref-type="bibr">[29]</xref>. Ebselen is known to form a covalent bond with CYS145. To explore whether the compound VS10 and VS12 are covalent inhibitors, or react with one or more cysteines. Two independent experiments were carried out to determine IC<sub>50</sub> values of VS10 and VS12 with different incubation time (<xref rid="t0020" ref-type="table">Table 4</xref>
, <xref rid="f0025" ref-type="fig">Fig. 5</xref>
, and <xref rid="f0030" ref-type="fig">Fig. 6</xref>
). The results showed that the inhibitory activity of VS10 remained unchanged with the prolongation of incubation time (<xref rid="t0020" ref-type="table">Table 4</xref> and <xref rid="f0025" ref-type="fig">Fig. 5</xref>). However, the inhibitory activity of VS12 against SARS-CoV-2 Mpro increased with the prolongation of incubation time (<xref rid="t0020" ref-type="table">Table 4</xref> and <xref rid="f0030" ref-type="fig">Fig. 6</xref>). Contrary to the stable IC<sub>50</sub> of VS10, the IC<sub>50</sub> of VS12 decreases as the incubation time increases. Therefore, we suspected that VS12 reacted with one or more cysteines and was the covalent inhibitor of SARS-CoV-2 Mpro. No matter what kind of interaction, the docking results show that the interaction sites are close to CYS145 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>).<table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>The inhibitory activities of VS10 and VS12 against SARS-CoV-2 Mpro with different incubation time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Incubation time (min)</th><th>VS10 &#x02013; IC<sub>50</sub> (&#x003bc;M)</th><th>VS12 &#x02013; IC<sub>50</sub> (&#x003bc;M)</th></tr></thead><tbody><tr><td>0</td><td>0.17&#x000a0;&#x000b1;&#x000a0;0.02</td><td>&#x02013;</td></tr><tr><td>2.5</td><td>0.20&#x000a0;&#x000b1;&#x000a0;0.02</td><td>&#x02013;</td></tr><tr><td>5</td><td>0.19&#x000a0;&#x000b1;&#x000a0;0.01</td><td>2.41&#x000a0;&#x000b1;&#x000a0;0.02</td></tr><tr><td>10</td><td>0.19&#x000a0;&#x000b1;&#x000a0;0.02</td><td>1.52&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td>20</td><td>0.18&#x000a0;&#x000b1;&#x000a0;0.05</td><td>0.84&#x000a0;&#x000b1;&#x000a0;0.07</td></tr><tr><td>60</td><td>0.25&#x000a0;&#x000b1;&#x000a0;0.04</td><td>0.64&#x000a0;&#x000b1;&#x000a0;0.08</td></tr></tbody></table></table-wrap><fig id="f0025"><label>Fig. 5</label><caption><p>The IC<sub>50</sub> curves of VS10 against SARS-CoV-2 Mpro with different incubation time of 0, 2.5, 5, 10, 20, and 60&#x000a0;min.</p></caption><graphic xlink:href="gr5_lrg"/></fig><fig id="f0030"><label>Fig. 6</label><caption><p>The IC<sub>50</sub> curves of VS12 against SARS-CoV-2 Mpro with different incubation time of 5, 10, 20, and 60&#x000a0;min.</p></caption><graphic xlink:href="gr6_lrg"/></fig></p></sec></sec><sec id="s0075"><label>4</label><title>Conclusions</title><p id="p0120">To combat COVID-19 pandemic, researchers around the globe are racing to come up with effective countermeasures. Promising progress has been made in developing vaccines and antiviral drugs. Antivirals are necessary complements of vaccines and are needs for post-infection treatment. In this study, a virtual screening protocol which includes drug-like molecules screening, PAINS and ADMET molecules filtering, docking-based drug design and cluster analysis, was developed. The final remaining top 37 molecules are further evaluated by biochemical evaluation and 2 molecules have shown good inhibitory activity. The binding modes of the two molecules were analyzed, which has shown that the drug leads identified can bind to the binding pocket of SARS-CoV-2 Mpro. HIS41, CYS145, MET165, and GLU166 are found to be the important amino acids for inhibitor binding. In this study, the virtual screening and high-throughput screening proved to be efficient strategies to discover antiviral leads against SARS-CoV-2 virus. The methods presented here can be greatly helpful in the rapid discovery of drug leads from a large compound library against new emerging infectious diseases which currently lack specific medicines.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0125">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><mixed-citation publication-type="other" id="h0005">A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B.L. Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.L.M. Poon, D.V. Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, V. Coronaviridae Study Group of the International Committee on Taxonomy of, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol. 5 (2020) 536&#x02013;544.</mixed-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>14</volume><year>2016</year><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Shuai</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Cui</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Bu</surname><given-names>Z.</given-names></name></person-group><article-title>Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>1016</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">32269068</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.-F.-W.</given-names></name><name><surname>Zhang</surname><given-names>A.J.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Poon</surname><given-names>V.-K.-M.</given-names></name><name><surname>Chan</surname><given-names>C.-C.-S.</given-names></name><name><surname>Lee</surname><given-names>A.-C.-Y.</given-names></name><name><surname>Chan</surname><given-names>W.-M.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Tsoi</surname><given-names>H.-W.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>K.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Cai</surname><given-names>J.-P.</given-names></name><name><surname>Kok</surname><given-names>K.-H.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Sridhar</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.-K.-W.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility</article-title><source>Clin. Infect. Dis.</source><volume>71</volume><year>2020</year><fpage>2428</fpage><lpage>2446</lpage><pub-id pub-id-type="pmid">32215622</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Kuppalli</surname><given-names>K.</given-names></name><name><surname>Rasmussen</surname><given-names>A.L.</given-names></name></person-group><article-title>A glimpse into the eye of the COVID-19 cytokine storm</article-title><source>EBioMedicine</source><volume>55</volume><year>2020</year><object-id pub-id-type="publisher-id">102789</object-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>S.</given-names></name><name><surname>Koma</surname><given-names>T.</given-names></name><name><surname>Doi</surname><given-names>N.</given-names></name><name><surname>Nomaguchi</surname><given-names>M.</given-names></name><name><surname>Adachi</surname><given-names>A.</given-names></name></person-group><article-title>Commentary: origin and evolution of pathogenic coronaviruses</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>811</fpage><pub-id pub-id-type="pmid">32373134</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Zhan</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>J.A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Tien</surname><given-names>P.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>5288</fpage><lpage>5295</lpage><pub-id pub-id-type="pmid">15827143</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31502247</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>X.M.</given-names></name><name><surname>Su</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Cen</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.K.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>1331</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">32321856</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Li-Li</given-names></name><name><surname>Wang</surname><given-names>Ye-Ming</given-names></name><name><surname>Wu</surname><given-names>Zhi-Qiang</given-names></name><name><surname>Xiang</surname><given-names>Zi-Chun</given-names></name><name><surname>Guo</surname><given-names>Li</given-names></name><name><surname>Xu</surname><given-names>Teng</given-names></name><name><surname>Jiang</surname><given-names>Yong-Zhong</given-names></name><name><surname>Xiong</surname><given-names>Yan</given-names></name><name><surname>Li</surname><given-names>Yong-Jun</given-names></name><name><surname>Li</surname><given-names>Hui</given-names></name><name><surname>Fan</surname><given-names>Guo-Hui</given-names></name><name><surname>Gu</surname><given-names>Xiao-Ying</given-names></name><name><surname>Xiao</surname><given-names>Yan</given-names></name><name><surname>Gao</surname><given-names>Hong</given-names></name><name><surname>Xu</surname><given-names>Jiu-Yang</given-names></name><name><surname>Yang</surname><given-names>Fan</given-names></name><name><surname>Wang</surname><given-names>Xin-Ming</given-names></name><name><surname>Wu</surname><given-names>Chao</given-names></name><name><surname>Chen</surname><given-names>Lan</given-names></name><name><surname>Liu</surname><given-names>Yi-Wei</given-names></name><name><surname>Liu</surname><given-names>Bo</given-names></name><name><surname>Yang</surname><given-names>Jian</given-names></name><name><surname>Wang</surname><given-names>Xiao-Rui</given-names></name><name><surname>Dong</surname><given-names>Jie</given-names></name><name><surname>Li</surname><given-names>Li</given-names></name><name><surname>Huang</surname><given-names>Chao-Lin</given-names></name><name><surname>Zhao</surname><given-names>Jian-Ping</given-names></name><name><surname>Hu</surname><given-names>Yi</given-names></name><name><surname>Cheng</surname><given-names>Zhen-Shun</given-names></name><name><surname>Liu</surname><given-names>Lin-Lin</given-names></name><name><surname>Qian</surname><given-names>Zhao-Hui</given-names></name><name><surname>Qin</surname><given-names>Chuan</given-names></name><name><surname>Jin</surname><given-names>Qi</given-names></name><name><surname>Cao</surname></name></person-group><article-title>Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study</article-title><source>Chinese Med. J.</source><year>2015</year><fpage>1015</fpage><lpage>1024</lpage></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Khalifa</surname><given-names>S.A.M.</given-names></name><name><surname>Yosri</surname><given-names>N.</given-names></name><name><surname>El-Mallah</surname><given-names>M.F.</given-names></name><name><surname>Ghonaim</surname><given-names>R.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Musharraf</surname><given-names>S.G.</given-names></name><name><surname>Du</surname><given-names>M.</given-names></name><name><surname>Khatib</surname><given-names>A.</given-names></name><name><surname>Xiao</surname><given-names>J.</given-names></name><name><surname>Saeed</surname><given-names>A.</given-names></name><name><surname>El-Seedi</surname><given-names>H.H.R.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name><name><surname>El-Seedi</surname><given-names>H.R.</given-names></name></person-group><article-title>Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic</article-title><source>Phytomedicine</source><volume>153311</volume><year>2020</year></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>M.</given-names></name><name><surname>Abdelrahman</surname><given-names>A.</given-names></name><name><surname>Hussien</surname><given-names>T.</given-names></name><name><surname>Badr</surname><given-names>E.</given-names></name><name><surname>Mohamed</surname><given-names>T.</given-names></name><name><surname>El-Seedi</surname><given-names>H.</given-names></name><name><surname>Pare</surname><given-names>P.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name><name><surname>Hegazy</surname><given-names>M.E.</given-names></name></person-group><article-title>In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors</article-title><source>Comput. Biol. Med.</source><year>2020</year><fpage>126</fpage></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Curth</surname><given-names>U.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Sauerhering</surname><given-names>L.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Rox</surname><given-names>K.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">32198291</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>J.</given-names></name><name><surname>Rajendran</surname><given-names>V.</given-names></name><name><surname>Purohit</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><article-title>Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors</article-title><source>J. Biomol. Struct. Dyn.</source><volume>10</volume><year>2020</year><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Narkhede</surname><given-names>R.R.</given-names></name><name><surname>Pise</surname><given-names>A.V.</given-names></name><name><surname>Cheke</surname><given-names>R.S.</given-names></name><name><surname>Shinde</surname><given-names>S.D.</given-names></name></person-group><article-title>Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): In-silico evidences</article-title><source>Nat. Prod. Bioprospect.</source><volume>10</volume><year>2020</year><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">32557405</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>Purohit</surname><given-names>R.</given-names></name></person-group><article-title>Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs</article-title><source>Comput. Biol. Med.</source><volume>128</volume><year>2021</year><object-id pub-id-type="publisher-id">104117</object-id></element-citation></ref><ref id="b0100"><label>20</label><mixed-citation publication-type="other" id="h0100">T. Lamichhane, M. Ghimire, Structural analysis of COVID-19 main protease and its interaction with the inhibitor N3 (2020).</mixed-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Bhardwaj</surname><given-names>V.</given-names></name><name><surname>Sharma</surname><given-names>J.</given-names></name><name><surname>Das</surname><given-names>P.</given-names></name><name><surname>Purohit</surname><given-names>R.</given-names></name></person-group><article-title>Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants</article-title><source>Genomics</source><year>2020</year></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Pu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name></person-group><article-title>Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation</article-title><source>J. Comput. Aided Mol. Des.</source><volume>32</volume><year>2018</year><fpage>901</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">30182144</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Lagorce</surname><given-names>D.</given-names></name><name><surname>Maupetit</surname><given-names>J.</given-names></name><name><surname>Baell</surname><given-names>J.</given-names></name><name><surname>Sperandio</surname><given-names>O.</given-names></name><name><surname>Tuffery</surname><given-names>P.</given-names></name><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Galons</surname><given-names>H.</given-names></name><name><surname>Villoutreix</surname><given-names>B.</given-names></name></person-group><article-title>The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections</article-title><source>Bioinformatics (Oxford, England)</source><volume>27</volume><year>2011</year><fpage>2018</fpage><lpage>2020</lpage></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Desai</surname><given-names>P.V.</given-names></name><name><surname>Arimoto</surname><given-names>R.</given-names></name><name><surname>Desino</surname><given-names>K.E.</given-names></name><name><surname>Fischer</surname><given-names>H.</given-names></name><name><surname>Keefer</surname><given-names>C.E.</given-names></name><name><surname>Petersson</surname><given-names>C.</given-names></name><name><surname>Winiwarter</surname><given-names>S.</given-names></name><name><surname>Broccatelli</surname><given-names>F.</given-names></name></person-group><article-title>In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development</article-title><source>J. Med. Chem.</source><volume>60</volume><year>2017</year><fpage>9097</fpage><lpage>9113</lpage><pub-id pub-id-type="pmid">28609624</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Venkatapathy</surname><given-names>R.</given-names></name><name><surname>Moudgal</surname><given-names>C.</given-names></name><name><surname>Bruce</surname><given-names>R.</given-names></name></person-group><article-title>Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction</article-title><source>J. Chem. Inf. Model.</source><volume>44</volume><year>2004</year><fpage>1623</fpage><lpage>1629</lpage></element-citation></ref><ref id="b0130"><label>26</label><mixed-citation publication-type="other" id="h0130">D. Diller, K. Merz, K. Jr, High throughput docking for library design and library prioritization, Proteins: Struct. Funct. Bioinf 43 (2001) 113&#x02013;124.</mixed-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Gareth</surname><given-names>Jones</given-names></name><name><surname>Peter</surname><given-names>Willett</given-names></name><name><surname>Robert</surname><given-names>Glen</given-names></name></person-group><article-title>Development and validation of a genetic algorithm for flexible docking</article-title><source>J. Mol. Biol.</source><volume>267</volume><year>1997</year><fpage>727</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">9126849</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>G.</given-names></name><name><surname>Willett</surname><given-names>P.</given-names></name><name><surname>Glen</surname><given-names>R.C.</given-names></name></person-group><article-title>A genetic algorithm for flexible molecular overlay and pharmacophore elucidation</article-title><source>J. Comput.-Aided Mol. Des.</source><volume>9</volume><year>1995</year><fpage>532</fpage><pub-id pub-id-type="pmid">8789195</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>C.</given-names></name><name><surname>Duan</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>You</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Guddat</surname><given-names>L.W.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title><source>Nature</source><volume>582</volume><year>2020</year><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H.-X.</given-names></name><name><surname>Yao</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>W.-F.</given-names></name><name><surname>Li</surname><given-names>M.-J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>W.-J.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Ke</surname><given-names>C.-Q.</given-names></name><name><surname>Hu</surname><given-names>H.-C.</given-names></name><name><surname>Gao</surname><given-names>M.-N.</given-names></name><name><surname>Yu</surname><given-names>K.-Q.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>J.-S.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.-K.</given-names></name><name><surname>Xiao</surname><given-names>G.-F.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>D.-W.</given-names></name><name><surname>Zuo</surname><given-names>J.-P.</given-names></name><name><surname>Jiang</surname><given-names>H.-L.</given-names></name><name><surname>Bai</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.-C.</given-names></name></person-group><article-title>Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients</article-title><source>Acta Pharmacol. Sin.</source><volume>41</volume><year>2020</year><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">32737471</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Salentin</surname><given-names>S.</given-names></name><name><surname>Schreiber</surname><given-names>S.</given-names></name><name><surname>Haupt</surname><given-names>V.</given-names></name><name><surname>Adasme</surname><given-names>M.</given-names></name><name><surname>Schroeder</surname><given-names>M.</given-names></name></person-group><article-title>PLIP: fully automated protein-ligand interaction profiler</article-title><source>Nucleic Acids Res.</source><volume>43</volume><year>2015</year><fpage>443</fpage><lpage>447</lpage></element-citation></ref><ref id="b0160"><label>32</label><mixed-citation publication-type="other" id="h0160">C. Ma, Y. Hu, J. Townsend, P. Lagarias, M. Marty, A. Kolocouris, J. Wang, Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors (2020) 1265&#x02013;1277.</mixed-citation></ref></ref-list><sec id="s0085" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary material</title><p id="p0140">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0010"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.doc"/></supplementary-material>
</p><p id="p0145">
<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 2</title></caption><media xlink:href="mmc2.zip"/></supplementary-material>
</p></sec><ack id="ak005"><title>Acknowledgements</title><p id="p0130">This project was financially supported by Basic Research Plan of Yunnan Provincial Science and Technology Department (Grant No: 202001AS070026), Science and Technology Planning Project of Sichuan Province (Grant No: 2019YFS0095), and the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100011238</institution-id><institution>State Key Laboratory of Phytochemistry and Plant Resources in West China</institution></institution-wrap></funding-source> (Grant No: P2017-KF07, P2018-KF14). Supercomputing Center of Sichuan University of Science &#x00026; Engineering Provides Computing Resources.</p></ack><fn-group><fn id="s0080" fn-type="supplementary-material"><label>Appendix A</label><p id="p0135">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bioorg.2021.104767" id="ir035">https://doi.org/10.1016/j.bioorg.2021.104767</ext-link>.</p></fn></fn-group></back></article>